Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revisiting prognostic biomarkers in gastrointestinal stromal tumor: the potential role of ETV1 polymorphisms.

Journal of gastrointestinal oncology·2026
Same author

Representation of Patients From South America in Sarcoma Clinical Trials.

JAMA network open·2026
Same author

Immune checkpoint inhibitors combined with tyrosine kinase inhibitors for soft-tissue sarcomas: a systematic review and single-arm meta-analysis.

The oncologist·2025
Same author

Fumarate hydratase (FH)-deficient uterine leiomyoma mimicking malignancy: A diagnostic challenge.

Radiology case reports·2025
Same author

Tarlatamab Exposure-Efficacy and Exposure-Safety Relationships to Inform Dose Selection in Patients with Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Improving thyroid disorder diagnosis via innovative stacking ensemble learning model.

Digital health·2025

Related Experiment Video

Updated: Nov 16, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.3K

Systemic Options for Malignant Peripheral Nerve Sheath Tumors.

Ayesha Hassan1,2, Roberto Carmagnani Pestana3, Amanda Parkes4,5

  • 1Department of Medicine, Division of Hematology, Medical Oncology, and Palliative Care, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.

Current Treatment Options in Oncology
|February 28, 2021
PubMed
Summary

Malignant peripheral nerve sheath tumors (MPNSTs) are challenging to treat, often recurring and metastasizing. Current therapies, based on soft tissue sarcoma treatments, show limited success, especially for neurofibromatosis type 1 (NF1)-associated MPNST, highlighting the need for new strategies.

Keywords:
ChemotherapyMalignant peripheral nerve sheath tumorMetastaticNeurofibromatosisRas

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.4K
Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management
03:53

Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management

Published on: March 15, 2024

2.5K

Related Experiment Videos

Last Updated: Nov 16, 2025

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

2.3K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.4K
Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management
03:53

Author Spotlight: Regenerative Peripheral Nerve Interface (RPNI) Surgery in Postamputation Pain Management

Published on: March 15, 2024

2.5K

Area of Science:

  • Oncology
  • Cancer Biology
  • Genetics

Background:

  • Malignant peripheral nerve sheath tumors (MPNSTs) are rare, aggressive cancers with high recurrence and metastasis rates.
  • Current treatment strategies for MPNSTs are largely based on soft tissue sarcoma protocols, yielding suboptimal outcomes.
  • The pathophysiology involves neurofibromin loss and Ras pathway activation, yet targeted therapies have been unsuccessful.

Purpose of the Study:

  • To review the current therapeutic landscape for MPNSTs.
  • To highlight the limitations of existing treatments, particularly for neurofibromatosis type 1 (NF1)-associated MPNST.
  • To emphasize the critical need for novel therapeutic strategies informed by preclinical research.

Main Methods:

  • Literature review of MPNST pathophysiology and treatment responses.
  • Analysis of current clinical practices and systemic therapy regimens.
  • Evaluation of the efficacy of standard chemotherapy agents like anthracyclines, ifosfamide, and etoposide.

Main Results:

  • MPNSTs exhibit poor response to conventional systemic therapies, including anthracycline-based regimens.
  • Neurofibromatosis type 1 (NF1)-associated MPNST shows a worse prognosis and reduced response to therapy compared to sporadic MPNST.
  • Existing treatments do not adequately address the unique biology of MPNST, leading to limited clinical benefit.

Conclusions:

  • Novel therapeutic strategies are urgently required for MPNST, especially for NF1-associated cases.
  • Preclinical studies are essential to identify and validate new therapeutic targets and agents.
  • Future clinical trials must be informed by a deeper understanding of MPNST biology to improve patient outcomes.